Subcutaneous formulations of Apellis’ pegcetacoplan and Alexion’s Ultomiris in PNH draw doubt for wide utility

Frequency of treatment is a notable deciding factor for patients in choosing their preferred route of administration in first-line PNH. Credit: Shutterstock + Rahman Aziz.



  • pegcetacoplan and Ultomiris